Octimet Oncology N.V. out-licensed the greater China rights for its assets to Allist Pharmaceuticals Co., Ltd. in August 2020. Allist Pharmaceuticals currently drives the clinical development of Octimet’s lead compound, OMO-1, initially focusing on expanding the combination data with Allist’s third generation EGFR TKI Furmonertinib (AST2818). In China, more than 38% of NSCLC patients harbor activating EGFR mutations, making the region ideal for completing expanded clinical efficacy studies more rapidly whilst addressing a large potential market.